

1 **Full Title:** Clinical course and potential predictive factors for pneumonia of adult patients
2 with Coronavirus Disease 2019 (COVID-19): a retrospective observational analysis of 193
3 confirmed cases in Thailand

4 **Short Title:** Clinical course and predictive factors for COVID-19 pneumonia in Thailand

5 **Authors:**

6 Wannarat A. Pongpirul^{1*}, Surasak Wiboonchutikul^{1*}, Lantharita Charoenpong¹, Nayot
7 Panitantum¹, Apichart Vachiraphan¹, Sumonmal Uttayamakul¹, Krit Pongpirul^{2,3}, Weerawat
8 Manosuthi^{1¶}, Wisit Prasithsirikul^{1¶}

9 **Affiliations:**

10 ¹Bamrasnaradura Infectious Diseases Institute, Department of Disease Control, Ministry of
11 Public Health, Nonthaburi, Thailand

12 ²Department of Preventive and Social Medicine, Faculty of Medicine, Chulalongkorn
13 University, Bangkok, Thailand

14 ³Department of International Health, Johns Hopkins Bloomberg School of Public Health,
15 Baltimore, MD, USA

16 *These first authors contributed equally to this article

17 ¶These senior authors contributed equally to this article

18 **Corresponding author:** Surasak Wiboonchutikul, M.D.

19 Bamrasnaradura Infectious Diseases Institute, Department of Disease Control, Ministry of
20 Public Health, Nonthaburi, 11000, Thailand, Email: surasakwiboon@gmail.com

21 Tel: +66 (0)2-590-3408, +66 (0)8-9918-3909, Fax: +66 (0)2-590-3411

22

Abstract

23 **Background**

24 Clinical spectrum of Coronavirus Disease 2019 (COVID-19) remains unclear, especially with
25 regard to the presence of pneumonia. We aimed to describe the clinical course and final
26 outcomes of adult patients with laboratory-confirmed COVID-19 in the full spectrum of
27 disease severity. We also aimed to identify potential predictive factors for COVID-19
28 pneumonia.

29 **Methods and findings**

30 We conducted a retrospective study among adult patients with laboratory-confirmed
31 COVID-19 who were hospitalized at Bamrasnaradura Infectious Diseases Institute, Thailand,
32 between January 8 and April 16, 2020. One-hundred-and-ninety-three patients were included.
33 The median (IQR) age was 37.0 (29.0-53.0) years, and 58.5% were male. More than half
34 (56%) of the patients were mild disease severity, 22% were moderate, 14% were severe, and
35 3% were critical. Asymptomatic infection was found in 5%. The final clinical outcomes in
36 189 (97.9%) were recovered and 4 (2.1%) were deceased. The incidence of pneumonia was
37 39%. In multivariable logistic regression, increasing age (OR 2.55 per 10-year increase from
38 30 years old; 95% CI, 1.67-3.90; $p < 0.001$), obesity (OR 8.74; 95% CI, 2.06-37.18; $p = 0.003$),
39 and higher temperature at presentation (OR 4.59 per 1°C increase from 37.2 °C; 95% CI,
40 2.30-9.17; $p < 0.001$) were potential predictive factors for COVID-19 pneumonia.

41 **Conclusion**

42 Across the spectrum of disease severities, most patients with COVID-19 in our cohort had
43 good final clinical outcomes. COVID-19 pneumonia was found in one-third of them. Older

44 age, obesity, and higher fever at presentation were independent predictors of COVID-19
45 pneumonia.

46

47 **Author summary**

48 This report describes the clinical course and final clinical outcomes of the full spectrum of
49 disease severity of Coronavirus Disease 2019 (COVID-19) and evaluates risk factors of
50 pneumonia in 193 laboratory-confirmed cases of COVID-19 in the Bamrasnaradura
51 Infectious Diseases Institute, Thailand. The majority of patients with COVID-19 had mild
52 disease. COVID-19 pneumonia was found in approximately 40% of patients. Older age,
53 obesity, and higher grade of fever at presentation were independent risk factors of pneumonia
54 in adult patients with COVID-19. Most patients in our cohort recovered and were discharged
55 from hospital (recovery rate, 98%). Our findings can help the public health systems to
56 estimate the burden of the disease and identify vulnerable patients in a timely manner.

57 **Introduction**

58 Coronavirus Disease 2019 (COVID-19) is the most recent emerging infectious disease, and it
59 is caused by novel Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) [1].
60 COVID-19 was first identified in China in December 2019 [2], and has become a global
61 menace with a great impact on the health systems of affected countries. Several studies have
62 described the demographic and clinical characteristics, disease severity, and treatment
63 outcomes of patients with COVID-19 [3-8]. These reports focused on the findings of patients
64 with moderate and severe diseases and most of the disease severity assessments were based
65 on evaluation at the time of admission, which were likely for triage purpose. The temporal
66 clinical progression during hospitalization was well documented [9, 10], disease severity at
67 admission can change during hospital stay and can also differ from that at discharge. Also,

68 the final clinical outcomes defined as recovered or deceased in the published reports could
69 not be fully established due to the fact that a number of the patients were still hospitalized at
70 the time of data analysis [3-6, 11, 12]. Thus, a complete picture and the final clinical
71 outcome, especially the rate of recovery, of patients with COVID-19 are still uncertain.

72 COVID-19 has been categorized into a range of clinical severity including,
73 asymptomatic, mild, moderate (non-severe pneumonia), severe (severe pneumonia), and
74 critical illness [13, 14]. Data from a large cohort from China showed 81% of patients had a
75 mild disease while 14% were severe and 5% developed critical illness [15]. Nevertheless,
76 patients defined as ‘mild’ in the Chinese nationwide survey varied from having minimal
77 symptoms without lung involvement to having early pneumonia. Data on COVID-19 patients
78 with both mild disease and mild pneumonia are lacking. Cases defined as ‘non-severe’ were
79 excluded in a recent randomized controlled trial on favipiravir [16]. The incidence and risk
80 factors of pneumonia of any severity in SARS-CoV-2-infected patients are also unknown.
81 Understanding the full spectrum of COVID-19, rather than only the more severe end of the
82 disease, would facilitate public health systems to estimate the burden of the disease and to
83 identify vulnerable patients earlier.

84 On January 13, 2020, Thailand reported a confirmed case of COVID-19, the first
85 recorded case outside of China [17]. This case was admitted to the Bamrasnaradura
86 Infectious Diseases (BIDI), which the Thai Ministry of Public Health designated as the
87 national infectious disease referral hospital for the COVID-19 outbreak. As of May 29, 2020,
88 3,076 patients with confirmed cases of COVID-19 had been reported in Thailand [18].

89 This study aimed to present details of all adult hospitalized patients with laboratory-
90 confirmed COVID-19 who were admitted to our institute regardless of the severity of their

91 disease. We described the clinical course and final outcome (recovered or deceased) of the
92 disease. Potential predictive factors of COVID-19 pneumonia were also investigated.

93 **Methods**

94 **Patients**

95 BIDI is the main public health institution under the Department of Disease Control, Ministry
96 of Public Health of Thailand responsible for testing and treating emerging infectious diseases
97 including COVID-19. All individuals who were diagnosed as COVID-19, according to the
98 WHO interim guidance [13] were admitted at the institute, regardless of the severity of their
99 disease. BIDI's protocol requires nasopharyngeal and throat swab samples to be obtained to
100 test for SARS-CoV-2 by real-time reverse-transcription–polymerase-chain-reaction (RT-
101 PCR) assay at two-day intervals during hospitalization, until two consecutive negative results
102 at least 24 hours apart were achieved. Baseline chest radiograph was performed in every
103 patient at admission. The need for follow-up chest radiograph during admission was based on
104 the judgement of each attending physicians. The patients were discharged if they met the
105 following criteria: 1) resolution of fever without the use of antipyretics \geq 48 hours, 2)
106 improvement in respiratory symptoms with oxygen saturation \geq 95% while they were
107 breathing ambient air, and 3) samples from nasopharyngeal and throat swab tested negative
108 for SARS-CoV-2 by real-time RT-PCR. We conducted a retrospective cohort study among
109 all adult patients aged \geq 18 years with laboratory-confirmed COVID-19 who were
110 hospitalized at BIDI, between January 8 and April 16, 2020. The hospital outcomes were
111 monitored until discharges or death. The study was reviewed and approved by the BIDI's
112 Institutional Review Board (S012h_63_ExpD).

113 **Definitions**

114 A laboratory-confirmed COVID-19 was defined as detecting SARS-CoV-2 RNA in
115 nasopharyngeal and throat swab specimens by RT-PCR assay. Fever was defined as an
116 axillary temperature of $\geq 37.3^{\circ}\text{C}$. Defervescence was defined as resolution of fever (axillary
117 temperature $< 37.3^{\circ}\text{C}$) without the use of fever-reducing medications. Pneumonia was
118 diagnosed by the presence of respiratory symptoms and opacity on chest radiography.
119 Pneumonia with detection of SARS-CoV-2 RNA from respiratory specimens was considered
120 as COVID 19-associated pneumonia. Acute respiratory distress syndrome (ARDS) was
121 determined according to the Berlin definition [19]. Acute kidney injury (AKI) was defined
122 according to Kidney Disease Improving Global Outcomes (KDIGO) guideline [20]. Obesity
123 was classified as body mass index (BMI) $\geq 30 \text{ kg/m}^2$ according to World Health Organization
124 (WHO) classification for overweight and obesity [21]

125 **Real-time reverse transcription-polymerase chain reaction assay for SARS-CoV-2**

126 Respiratory specimens were collected from the nasopharynx and oropharynx using synthetic
127 fiber or flocked swabs. The swabs from both sites were placed in the same tube to increase
128 viral detection. Samples were transported in a viral transport medium containing anti-fungal
129 and antibiotic supplements were used. Sputum specimens were collected from patients with
130 lower respiratory symptoms.

131 Total nucleic acid or viral RNA was extracted from the specimens and tested with
132 conventional nested RT-PCR for coronavirus family of the first two novel coronavirus cases
133 in Thailand. Both cases were confirmed as Wuhan human novel coronavirus 2019 by two
134 reference laboratories—the Thailand National Institute of Health, Ministry of Public Health
135 and Emerging Infectious Disease Health Sciences Center, King Chulalongkorn Memorial
136 Hospital, Thai Red Cross Society—using whole-genome sequencing comparison to the
137 Wuhan reference virus (posted in GenBank, accession number MN908947). After Wuhan

138 human novel coronavirus 2019 sequence data were available, real-time RT-PCR with SARS-
139 CoV-2-specific primers and probes were developed to detect the specific gene areas using the
140 WHO protocol. Real-time RT-PCR testing was based on fluorescent PCR and probes consist
141 of a reporter dye and quencher dye. The PCR instrument was automatically amplified and
142 detect the fluorescent signal. To avoid contamination, non-template or negative controls were
143 included in every PCR run. Human housekeeping gene was used as an internal control to
144 monitor the process of specimen collection and extraction. To confirm COVID-19 infection
145 at the early phase of the COVID-19 outbreak in January and February 2020, SARS-CoV-2
146 RNA had to be detected by two independent laboratories.

147 At BIDI, we used two real-time RT-PCR techniques to detect SARS-CoV-2. First, the
148 COVID-19 Coronavirus Real Time PCR Kit (Jiangsu Bioperfectus Technologies Co.,Ltd.;
149 WHO Product Code JC10223-1NW-25T or JC10223-1NW-25T) was used for detecting the
150 Open Reading Frame gene region (ORF 1ab) and viral nucleocapsid region (N gene)
151 according to the recommendation of the Chinese CDC-. Second, the Real-Time Fluorescence
152 Detection RT-PCR kit (BGI technology) was concurrently used for detecting the ORF 1ab
153 gene. After March 31, 2020, Cobas[®] SARS-CoV-2 qualitative assay for use on the Cobas[®]
154 6800/8800 Systems (Roche Molecular Systems, Inc.) was used at BIDI. Both ORF 1ab and E
155 gene were designed for SARS-CoV-2 detection according to WHO recommendation.

156 **Data collection**

157 Demographic, epidemiological, clinical, hospital courses, investigation, and treatment data of
158 all consecutive laboratory-confirmed cases were extracted from medical records reviewed by
159 four attending physicians responsible for the patients with COVID-19 at BIDI. Chest
160 radiography interpretation was based on reports by radiologists and independently rechecked

161 by a pulmonologist during the data extraction. The severity of illness of each patient was
162 evaluated at the time of discharge or death by the study team.

163 **Clinical outcomes**

164 The patients who met the discharged criteria were defined as recovered. All laboratory-
165 confirmed cases who died during hospitalization regardless of any negative follow-up RT-
166 PCR results defined as deceased. The severity of illness of each patient was classified
167 following the report of the WHO-China Joint mission on Coronavirus Disease 2019 [22]:
168 mild (the clinical symptoms were mild, and there was no sign of pneumonia on imaging),
169 moderate (fever and respiratory symptoms with radiological findings of pneumonia, but
170 without features of severe pneumonia), severe (respiratory rate ≥ 30 breaths/minute, oxygen
171 saturation $\leq 93\%$, PaO₂/FiO₂ ratio < 300 , and/or lung infiltrates $> 50\%$ of the lung field within
172 24-48 hours), and critical (respiratory failure, shock, and/or multiple organ failure).
173 Asymptomatic infection was defined as when patients had no symptoms or signs throughout
174 the course of the disease. Patients were categorized into two groups based on pneumonia
175 detection (pneumonia vs non-pneumonia).

176 **Statistics**

177 Descriptive data are presented as mean and standard deviation (SD), median and interquartile
178 range (IQR), and frequencies (%), as appropriate. No imputation was made for missing data.
179 The mean values of continuous variables with normal distribution between the pneumonia
180 and non-pneumonia groups were compared using Student's *t-test*. Categorical variables
181 between the pneumonia and non-pneumonia groups were compared using the Chi-squared
182 test and Fisher's exact test, as appropriate. Logistic regression analysis was used to determine
183 factors associated with pneumonia in patients with COVID-19. We excluded variables from
184 the logistic model if their nature was highly subjective (presenting symptoms that were

185 patient self-reported), if the data were not available $\geq 20\%$ of all cases (blood chemistry
186 results), or if they were correlated with pneumonia (e.g. high respiratory rate and low oxygen
187 saturation). Variables with p-value < 0.05 on univariate analysis were included in the
188 multiple logistic regression model. Collinearity diagnostics were performed for the
189 multivariable logistic regression analysis. A correlation of > 0.5 was considered risk of bias
190 estimation due to collinearity. All statistical analyses were performed using SPSS version
191 26.0 (IBM SPSS Statistics Subscription Trial). A p-value < 0.05 was considered statistically
192 significant

193 **Results**

194 **Patients' characteristics**

195 A total of 195 laboratory-confirmed SARS-CoV-2 infected patients were admitted to BIDI
196 during the study period. This included 11 patients previously reported during the early phase
197 of COVID-19 outbreak [23]. Of the 195 laboratory-confirmed SARS-CoV-2-infected
198 patients, 193 (99.0%) had either a recovered or deceased final clinical outcome. The other
199 two patients were referred to other hospitals before viral RNA clearance according to their
200 requests to be referred. Two consecutive negative RT-PCR results from nasopharyngeal and
201 throat swab were obtained in 82.4% and single negative results in 17.6%. The median (IQR)
202 age of the patients was 37.0 (29.0-53.0) years, 58.5 % were males, and 91.2% were Thai. The
203 median BMI (IQR) was 23.3 (20.4-25.9) kg/m^2 and 12.7% were obese. One-quarter of the
204 patients had one or more coexisting medical conditions, which was found less frequently in
205 mild cases. Hypertension, diabetes, and dyslipidemia were the most common comorbidities.
206 Of all cases, 79.3% were local transmission, and 20.7% were imported cases. The
207 epidemiological data showed that 34.7% had a history of contact with a confirmed COVID-
208 19 case, 20.7% had arrived from affected countries with widespread or ongoing transmission

209 of COVID-19 within 14 days before the onset of illness, 17.1% had attended or worked at
 210 crowded places, 22.8% were involved with a boxing stadium cluster, and only one patient
 211 was linked with a healthcare facility (Table 1).

212 **Table 1.** Baseline characteristics and initial findings of the study patients

	All (n=193)	Asymptomatic (n=10)	Mild (n=108)	Moderate (n=43)	Severe (n=26)	Critical (n=6)
Baseline characteristics						
Age, median (IQR), y	37.0 (29.0-53.0)	43.0 (31.3-56.3)	32.0 (26.0-40.5)	48.0 (34.0-59.0)	52.5 (46.5-56.3)	64.0 (41.8-72.3)
Age distribution, n (%)						
20-29 y	53 (27.5)	2 (20.0)	44 (40.7)	6 (14.0)	1 (3.8)	0
30-39 y	53 (27.5)	2 (20.0)	37 (34.3)	10 (23.3)	3 (11.1)	1 (16.7)
40-49 y	30 (15.5)	3 (30.0)	14 (13.3)	8 (18.6)	4 (15.4)	1 (16.7)
50-59 y	34 (17.6)	1 (10.0)	10 (9.3)	9 (20.9)	13 (50.0)	1 (16.7)
60-69 y	15 (7.8)	2 (20.0)	3 (2.8)	9 (20.9)	1 (3.8)	0
70-79 y	8 (4.1)	0	0	1 (2.3)	4 (15.4)	3 (50.0)
Gender, n (%)						
- Male	113 (58.5)	5 (50.0)	53 (49.1)	32 (74.4)	17 (65.4)	6 (100)
- Female	80 (41.5)	5 (50.0)	55 (50.9)	11 (25.6)	9 (34.6)	0
BMI, median (IQR), kg/m ²	23.3 (20.4-25.9)	22.8 (21.7-29.4)	21.6 (19.3-24.6)	25.4 (22.6-31.1)	25.1 (22.9-29.8)	24.2 (21.5-25.5)
Distribution of BMI (n=173), n (%)						
- <18.5	17 (9.8)	1 (14.3)	15 (14.9)	0	1 (4.2)	0
- 18.5-24.9	99 (57.2)	3 (42.9)	66 (65.3)	16 (45.7)	10 (41.7)	4 (66.7)
- 25.0-29.9	35 (20.2)	2 (28.6)	15 (14.9)	9 (25.7)	7 (29.2)	2 (33.3)
- ≥30.0	22 (12.7)	1 (14.3)	5 (5.0)	10 (28.6)	6 (25.0)	0
Nationality, n (%)						
- Thai	176 (91.2)	7 (70.0)	101 (93.5)	37 (86.0)	25 (96.2)	6 (100)
- Non-Thai	17 (8.8)	3 (30.0)	7 (6.5)	6 (14.0)	1 (3.8)	0
Type of infection, n (%)						
- Imported case	40 (20.7)	5 (50.0)	19 (17.6)	12 (27.9)	4 (15.4)	0
- Local transmission case	153 (79.3)	5 (50.0)	89 (82.4)	31 (72.1)	22 (84.6)	6 (100)
Transmission link, n (%)						
- Contact with a confirm case	67 (34.7)	4 (40.0)	47 (43.5)	12 (27.9)	4 (15.4)	0

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/) .

- Arrived from a country with widespread transmission of COVID-19 within 14 days before onset of illness	40 (20.7)	5 (50.0)	19 (17.6)	12 (27.9)	4 (15.4)	0
- Attended or worked at a crowded place	33 (17.1)	0	21 (19.4)	6 (14.0)	4 (15.4)	2 (33.3)
- Boxing stadium clusters	44 (22.8)	1 (10.0)	17 (15.7)	12 (27.9)	11 (42.3)	3 (50.0)
- Healthcare facility	1 (0.5)	0	0	0	1 (3.8)	0
- Unknown	8 (4.1)	0	4 (9.3)	1 (2.3)	6 (7.7)	1 (16.7)
Smoking (n=157), n (%)						
- Never	128 (81.5)	8 (88.9)	66 (80.5)	32 (80.0)	19 (86.4)	3 (75.0)
- Ever	29 (18.5)	1 (11.1)	16 (19.5)	8 (20.0)	3 (13.6)	1 (25.0)
Alcohol use (n=164), n (%)						
- No	112 (68.3)	5 (62.5)	55 (64.7)	28 (68.3)	21 (84.0)	3 (60.0)
- Yes	52 (31.7)	3 (37.5)	30 (35.3)	13 (31.7)	4 (16.0)	2 (40.0)
Coexisting conditions, n (%)						
- Any*	48 (24.9)	3 (30.0)	10 (9.3)	16 (37.2)	15 (57.7)	4 (66.7)
- Diabetes	16 (8.3)	1 (10.0)	3 (2.8)	2 (4.7)	7 (26.9)	3 (50.0)
- Hypertension	31 (16.1)	3 (30.0)	4 (3.7)	11 (25.6)	10 (38.5)	3 (50.0)
- Dyslipidemia	10 (5.2)	1 (10.0)	2 (1.9)	3 (7.0)	3 (11.5)	1 (16.7)
- Allergy	2 (1.0)	0	1 (0.9)	0	1 (3.8)	0
- Chronic pulmonary diseases	3 (1.6)	0	1 (0.9)	2 (4.7)	0	0
- Chronic heart diseases	2 (1.0)	0	0	1 (2.3)	1 (3.8)	0
- Chronic liver diseases	5 (2.6)	0	1 (0.9)	3 (7.0)	1 (3.8)	0
- HIV infection	2 (1.0)	0	1 (0.9)	0	1 (3.8)	0
Angiotensin-converting enzyme inhibitors use, n (%)	6 (3.1)	0	3 (2.8)	1 (2.3)	1 (3.8)	1 (16.7)
Angiotensin-receptor blockers use, n (%)	11 (5.7)	2 (20.0)	1 (0.9)	6 (14.0)	2 (7.7)	0
Days from onset of illness to the first visit, median (IQR)	3.0 (2.0-6.0)	-	3.0 (2.0-6.0)	3.0 (1.0-7.0)	4.5 (1.0-6.3)	4 (2.8-5.5)
Presenting symptoms*, n (%)						
- Fever	121 (62.7)	0	60 (55.6)	33 (76.7)	23 (88.5)	5 (83.3)
- Dry cough	95 (49.2)	0	50 (46.8)	25 (58.1)	18 (69.2)	2 (33.3)
- Productive cough	41 (21.2)	0	22 (20.4)	8 (18.6)	7 (26.9)	4 (67.7)
- Shortness of breath	25 (13.0)	0	8 (7.4)	8 (18.6)	8 (30.8)	1 (16.7)

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/) .

- Sore throat	54 (28.0)	0	42 (38.9)	10 (23.3)	1 (3.8)	1 (16.7)
- Rhinorrhea	55 (28.5)	0	41 (38.0)	10 (23.3)	4 (15.4)	0
- Fatigue	30 (15.5)	0	15 (13.9)	7 (16.3)	8 (30.8)	0
- Myalgia/body aches	69 (35.8)	0	32 (29.6)	20 (46.5)	12 (46.2)	5 (83.5)
- Headache	25 (13.0)	0	18 (16.3)	4 (9.3)	0	1 (16.7)
- Diarrhea	15 (7.8)	0	9 (8.3)	1 (2.3)	1 (3.8)	1 (16.7)
- Poor appetite	4 (2.1)	0	1 (0.9)	1 (2.3)	2 (7.7)	0
- Nausea or vomiting	5 (2.6)	0	1 (0.9)	1 (2.3)	3 (11.5)	0
- Reduced sense of taste	8 (4.1)	0	3 (2.8)	1 (2.3)	4 (15.4)	0
- Reduced sense of smell	11 (5.7)	0	7 (6.5)	1 (2.3)	3 (11.5)	0
- No symptoms	13 (6.7)	10 (100)	3 (2.8)	0	0	0
Vital signs at the first presentation, initial laboratory and radiographic findings						
Body temperature, mean (\pm SD) , °C	37.3 (0.8)	36.6 (0.3)	37.0 (0.6)	37.5 (1.0)	37.8 (1.1)	38.0 (0.8)
Body temperature range distribution (n=191), n (%)						
<37.3°C	115 (60.2)	10 (100)	77 (72.6)	19 (44.2)	9 (34.6)	0
37.3-38.0°C	46 (24.1)	0	24 (22.6)	12 (27.9)	6 (22.3)	4 (66.7)
38.1-39.0°C	20 (10.5)	0	4 (3.8)	9 (20.9)	6 (22.3)	1 (16.7)
>39.0°C	10 (5.2)	0	1 (0.9)	3 (7.0)	5 (19.2)	1 (16.7)
Respiratory rate, median (IQR) , breaths/min	18 (18-20)	18 (18-19)	18 (18-19)	18 (18-19)	20 (18-22)	20 (19-28)
Oxygen saturation at presentation, median (IQR) , %	98 (97-99)	99 (98-99)	99.0 (98- 100)	98 (97-99)	97 (95-98)	96 (88-98)
Initial laboratory findings						
White blood cell count, median (IQR), $\times 10^9$ /L	5.9 (4.6-7.1)	6.8 (5.8-7.7)	5.9 (4.7-7.3)	5.3 (4.1-6.2)	6.2 (5.4-8.0)	6.9 (4.8- 8.4)
Absolute neutrophil count, median (IQR), $\times 10^9$ /L	3.5 (2.6-4.9)	3.6 (2.7-5.1)	3.5 (2.7-4.8)	3.0 (2.2-4.0)	4.7 (3.2-6.3)	5.8 (4.1- 6.5)
Absolute lymphocyte count, median (IQR), $\times 10^9$ /L	1.6 (1.1-2.1)	2.0 (1.4-2.3)	1.8 (1.3-2.2)	1.4 (1.1-1.9)	1.3 (0.9-1.5)	0.8 (0.5- 0.9)
Absolute monocyte count, median (IQR), $\times 10^9$ /L	0.3 (0.2-0.5)	0.5 (0.3-0.5)	0.4 (0.2-0.5)	0.3 (0.2-0.5)	0.3 (0.2-0.4)	0.3 (0.2- 0.4)
Hemoglobin, median (IQR), g/dL	13.6 (12.6- 14.6)	13.5 (12.2- 13.7)	13.3 (12.5- 14.2)	13.9 (12.9- 14.9)	14.1 (12.3- 15.0)	13.6 (12.1- 14.3)
Platelet count, median (IQR), $\times 10^9$ /L	221 (181- 280)	243 (207-276)	240 (195- 300)	199 (164- 226)	204 (156- 260)	165 (162- 188)
Sodium level (n=96), median (IQR),	139 (137- 141)	141 (139-143)	140 (139- 141)	139 (137- 141)	137 (133- 141)	136 (133- 141)

mEq/L,	141)		141)	141)	139)	141)
Potassium level (n=96), median (IQR), mEq/L,	3.9 (3.6-4.2)	3.8 (2.9-3.9)	4.1 (3.9-4.3)	3.9 (3.6-4.1)	3.6 (3.4-4.3)	3.8 (3.2-4.0)
Chlorine level (n=96), median (IQR), mEq/L	102 (99-103)	102 (99-103)	102 (101-104)	102 (100-103)	98 (95-102)	102 (96-103)
Bicarbonate level (n=96), median (IQR), mEq/L	24 (23-25)	25 (23-27)	24 (22-25)	24 (23-25)	24 (21-25)	23 (18-26)
Creatinine, median (n=112), mg/dL,	0.8 (0.7-1.0)	0.8 (0.6-0.9)	0.7 (0.6-0.9)	0.9 (0.7-1.0)	0.8 (0.7-1.1)	1.1 (1.0-1.3)
Aspartate aminotransferase, (n=104), median (IQR), U/L,	24 (19-35)	21 (18-31)	21 (17-25)	28 (22-41)	33 (23-39)	78 (52-85)
Alanine aminotransferase (n=104), median (IQR), U/L	22 (15-33)	22 (16-23)	18 (12-25)	27 (20-41)	21 (14-38)	48 (41-64)
Rapid influenza diagnosis test, n (%)						
- Negative	140 (72.5)	6 (60.0)	74 (68.5)	37 (86.0)	19 (73.1)	4 (66.7)
- Positive	1 (0.5)	0	1 (0.9)	0	0	0
- Not tested	52 (26.9)	4 (60.0)	33 (30.6)	6 (14.0)	7 (26.9)	2 (33.3)
Initial chest film opacities, n (%)						
None	156 (80.8)	10 (100)	108 (100)	22 (51.2)	12 (46.2)	4 (66.7)
Unilateral	17 (8.8)	0	0	13 (30.2)	4 (15.4)	0
Bilateral	20 (10.4)	0	0	8 (18.6)	10 (38.5)	2 (33.3)

213 Abbreviations: BMI, body mass index; HIV, human immunodeficiency virus. * More than one pre-existing condition or
 214 presenting symptoms could be given for these characteristics

215 **At presentation**

216 Contact investigation was able to identify the date of disease contact in 83 (43.0%) patients.

217 Among this group, the median (IQR) incubation period among this group was 5.5 (3.0-8.0)

218 days. The median (IQR) time from onset of illness to the first visit was 3.0 (2.0-6.0) days.

219 Baseline clinical characteristics of the patients are shown in Table 1. Fever (62.7%) was the

220 most common presenting symptoms, followed by dry cough (49.2%). Coryza, including

221 rhinorrhea and sore throat, were reported in 28% of cases. Gastrointestinal symptoms were

222 initially present in less than 10% of the patients. At presentation, only 78 (39.8%) of patients

223 were found to have a fever by a thermometer measurement. The mean axillary temperature of
224 mild cases was 37.0 °C, whereas those of moderate and severe cases were more than 37.5 °C.
225 The patients with moderate and severe disease had laboratory abnormalities of greater
226 magnitude (e.g. lower absolute lymphocyte and platelet count). Rapid influenza diagnosis test
227 was done in 141 (73.0%) patients; only one patient tested positive for influenza A. Chest
228 radiography revealed no opacity in 80.8%, unilateral opacity in 8.8%, and bilateral opacities
229 in 10.4% of the patients.

230 **During hospitalization**

231 The median (IQR) time from onset of illness to hospitalization was 5.0 (3.0-7.0) days. The
232 median frequency of chest radiograph performed during admission was 3.0 (2.0-5.0). Follow-
233 up chest radiograph was done in 155 (80.3%) of the patients. Pneumonia was detected in 75
234 (38.9%) of the patients, of which 49.3% were upon admission and 50.7% were during
235 hospitalization. Among 38 patients who progressed to have pneumonia after admission,
236 diagnostic work up to rule out hospital-acquired pneumonia was performed. Only one patient
237 had *Hemophilus parainfluenzae* detected from sputum culture which was considered as co-
238 infection. Among the 75 cases with pneumonia, 34.7% were unilateral, and 65.3% were
239 bilateral. The median (IQR) time from onset of illness to pneumonia detection was 7.0 (5.0-
240 9.0) days. Fever was present in only 49.2% of all cases but was detected in 88% of patients
241 with pneumonia. Among febrile patients, non-pneumonia (mild) cases had a lower mean of
242 highest temperature during hospitalization than of those who had pneumonia (37.9 vs 38.8
243 °C). Of 121 patients who reported having had subjective fever prior to admission, 44 (36.4%)
244 had no fever for the entire length of hospital stay. Of 72 patients who reported no fever prior
245 to admission, 18 (25.0%) developed a fever during hospitalization. The median duration from
246 admission to defervescence was 5.0 (3.0-9.0) days. The median duration from admission to
247 defervescence in mild cases was the shortest (3.0 days) compared to higher severity disease

248 categories (Table 2). Seventy-four patients (38.3%) received supportive treatment while
 249 61.7% also received therapeutic options listed in the Thai treatment guideline for cases of
 250 COVID-19 infection (Table 2). Thirty-two patients (16.6%) were transferred to the intensive
 251 care unit (ICU). The median (IQR) duration from illness onset to ICU admission was 8.0
 252 (5.3-10.0) days. Oxygen saturation of < 95% was found in 18.1% of cases whereas 13.0%
 253 experienced a respiratory rate of ≥ 24 breaths/min, which only occurred in the pneumonia
 254 group. The median duration (IQR) from symptom onset to oxygen saturation < 95% and
 255 respiratory rate ≥ 24 breaths/min were 8.0 (7.0-9.0) and 9.0 (6.0-11.0) days, respectively.
 256 Supplemental oxygen by nasal cannula or face mask was administered in 18.7%, high-flow
 257 oxygen in 4.7% and mechanical ventilation in 2.6% of all the patients. The median duration
 258 (IQR) from illness onset to intubation was 9.0 (7.0-12.5) days. The median (IQR) duration of
 259 oxygen therapy was 5.0 (2.5-11.0) days. More than two weeks of oxygen therapy was
 260 required in critical cases. Moderate to severe ARDS was found in 3.1% whereas 3.6% of the
 261 patients developed AKI. The median (IQR) length of hospital stay was 12.0 (7.5-19.0) days.
 262 The median duration of viral RNA shedding after the onset of symptom was 16.0 (11.0-24.0)
 263 days. Severe cases had a longer viral shedding duration than the non-severe cases (Table 2).
 264 The longest observed duration of viral shedding was 45 days.

265 **Table 2.** Treatments and clinical course during hospitalization

	All (n=193)	Asymptomatic (n=10)	Mild (n=108)	Moderate (n=43)	Severe (n=26)	Critical (n=6)
Treatments						
Supportive, n (%)	74 (38.3)	9 (90.0)	53 (49.1)	10 (23.3)	2 (7.7)	0
Chloroquine monotherapy, n (%)	20 (10.4)	0	20 (18.5)	0	0	0
Chloroquine or hydroxychloroquine + boosted lopinavir or darunavir, n (%)	36 (18.7)	1 (10.0)	28 (25.9)	1 (2.3)	4 (15.4)	2 (33.3)
Hydroxychloroquine + azithromycin,	8 (4.1)	0	7 (6.5)	1 (2.3)	0	0

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/) .

n (%)						
Chloroquine or hydroxychloroquine + boosted lopinavir or darunavir + azithromycin, n (%)	5 (2.6)	0	0	1 (2.3)	3 (11.5)	1 (16.7)
Chloroquine or hydroxychloroquine + boosted lopinavir or darunavir + favipiravir , n (%)	38 (19.7)	0	0	27 (62.8)	10 (38.5)	1 (16.7)
Chloroquine or hydroxychloroquine + boosted lopinavir or darunavir + azithromycin + favipiravir, n (%)	12 (6.2)	0	0	3 (7.0)	7 (26.9)	2 (33.3)
Remdesivir, n (%)	7 (3.6)	0	0	0	5 (19.2)	2 (33.3)
Tocilizumab, n (%)	3 (1.6)	0	0	0	2 (8.0)	1 (16.7)
Corticosteroid, n (%)	2 (1.0)	0	0	0	0	2 (33.3)
Convalescent plasma, n (%)	2 (1.0)	0	0	0	0	2 (33.3)
Antibiotics, n (%)	27 (14.0)	0	3 (2.8)	7 (16.3)	12 (46.2)	5 (83.3)
Oxygen therapy, n (%)						
- Nasal cannula/face mask	36 (18.7)	0	0	4 (9.3)	26 (100)	6 (100)
- High-flow oxygen	9 (4.7)	0	0	0	5 (19.2)	4 (66.7)
- Invasive ventilation	5 (2.6)	0	0	0	0	5 (83.3)
Days of oxygen therapy, median (IQR)	5.0 (2.5-11.0)	-	-	2.0 (1.3-2.8)	5.5 (3.0-11.0)	> 18.0
Extracorporeal membrane oxygenation, n (%)	1 (0.51)	0	0	0	0	1 (16.7)
Continuous renal replacement therapies, n (%)	1 (0.51)	0	0	0	0	1 (16.7)
Clinical course, complications and final clinical outcomes						
Days from onset of illness to admission, median (IQR)	5.0 (3.0-7.0)	-	5.0 (3.0-7.0)	5.0 (3.0-9.0)	5.5 (4.0-9.0)	5.5 (2.8-7.0)
Fever during hospitalization, n (%)	95 (49.2)	0	29 (26.9)	35 (81.4)	25 (96.2)	6 (100)
Highest temperature during hospitalization, mean (±SD), °C	38.5 (0.8)	< 37.3	37.9 (0.5)	38.5 (0.6)	39.0 (0.8)	39.5 (0.9)
- Days from admission to defervescence, median (IQR)	5.0 (3.0-9.0)	-	3.0 (1.0-5.5)	6.0 (3.0-9.0)	7.0 (5.0-11.5)	15.0
Worst opacity in chest film, n (%)						
None	118 (61.1)	10 (100)	108 (100)	0	0	0
Unilateral	26 (13.5)	0	0	24 (55.8)	2 (7.7)	0
Bilateral	49 (25.4)	0	0	19 (44.2)	24 (92.3)	6 (100)

Oxygen saturation < 95%, n (%)	35 (18.1)	0	0	3 (7.0)	26 (100)	6 (100)
Respiratory rate ≥ 24 breaths/min, n (%)	25 (13.0)	0	0	2 (4.7)	17 (65.4)	6 (100)
ICU admission, n (%)	32 (16.6)	0	0	6 (14.0)	20 (76.9)	6 (100)
ARDS, n (%)	6 (3.1)	0	0	0	0	6 (100)
Acute kidney injury, n (%)	7 (3.6)	0	0	2 (4.7)	0	5 (83.3)
Co-infection*, n (%)	8 (4.1)	0	3 (2.8)	2 (4.7)	1 (3.7)	2 (33.3)
Days of hospitalization, median (IQR)	12.0 (7.5-19.0)	8.5 (5.8-20.8)	10.5 (7.0-16.0)	13.0 (9.0-18.0)	16.0 (12.0-22.3)	32.5 (19.3-51.2)
Days of viral RNA shedding after onset of illness, median (IQR)	16.0 (11.0-24.0)	6.0 (4.8-19.0)	13.0 (9.0-21.0)	16.0 (12.0-24.0)	20.5 (13.0-24.0)	26.5 (21.5-34.5)
Final clinical outcome, n (%)						
- Recovered	189 (97.9)	10 (100)	108 (100)	43 (100)	26 (100)	2 (33.3)
- Deceased	4 (2.1)	0	0	0	0	4 (66.7)
- Remained hospitalized, n (%)	0	0	0	0	0	0

266 Abbreviations: ARDS, acute respiratory distress syndrome; ICU, intensive care unit. * Pulmonary tuberculosis in 2, *H.*

267 *influenzae* in 2, Influenza A in 1, adenovirus in 1, *H. parainfluenzae* in 1, *K. pneumoniae* in 1

268 **Final clinical outcomes and factors associated with pneumonia**

269 Of all cases, 189 (97.9%) were recovered and discharged whereas 4 (2.1%) were deceased.

270 The degree of disease severity was classified as asymptomatic in 5.2%, mild in 55.9%,


271 moderate (non-severe pneumonia) in 22.3%, severe (severe pneumonia) in 13.5%, and

272 critical in 3.1% (Fig 1). According to the Chinese CDC definition [15], 83.4% of the patients

273 were considered mild, 13.5% were severe, and 3.1% were critical. The median time (IQR)

274 from the onset of illness to death was 30.0 (18.0-49.5) days.

275 **Figure 1.** Disease severity classification



276

277 Table 3 demonstrates that patients with pneumonia were older ($p < 0.001$), more likely
 278 to be male ($p = 0.001$), more likely to be obese ($p = 0.001$), and were different in many
 279 presenting symptoms ($p < 0.05$) than those without pneumonia. Cases with pneumonia also
 280 had more comorbidities ($p < 0.001$), higher body temperature ($p < 0.001$), and lower oxygen
 281 saturation at presentation ($p < 0.001$) than the non-pneumonia cases. Patients without
 282 pneumonia more frequently complained of a runny nose ($p = 0.022$) and sore throat ($p = 0.003$)
 283 than those with pneumonia. Cases with pneumonia also had a higher proportion of febrile
 284 illness during hospitalization ($p < 0.001$), longer duration from admission to defervescence
 285 ($p < 0.001$), longer hospital stay ($p < 0.001$), and longer viral shedding duration ($p < 0.001$) than
 286 patients without pneumonia.

287 **Table 3.** Baseline characteristics, initial laboratory findings, and outcomes of patients with
 288 COVID-19 comparing the pneumonia group to the non-pneumonia group ($n = 193$)

	Non-pneumonia (n=118)	Pneumonia (n=75)	p-value
Baseline characteristics			

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/) .

Age, median (IQR), y	33.0 (26.0-42.3)	51.0 (38.0-59.0)	<0.001
Gender, n (%)			0.001
- Male	58 (49.2)	55 (73.3)	
- Female	60 (50.8)	20 (26.7)	
BMI, median (IQR), kg/m ²	21.8 (19.4-24.7)	25.1 (22.8-29.9)	<0.001
- Obesity (BMI ≥30), n (%)	6 (5.1)	16 (21.3)	0.001
Nationality, n (%)			0.934
- Thai	108 (91.5)	68 (90.7)	
- Non-Thai	10 (8.5)	7 (9.3)	
Type of infection, n (%)			0.853
- Imported cases	24 (20.3)	16 (21.3)	
- Local transmission cases	94 (79.7)	59 (78.7)	
Transmission link, n (%)			0.007
- Contact with a confirm case	51 (43.2)	16 (21.3)	
- Travel history within 14 days before onset of symptom	24 (20.3)	16 (21.3)	
- Attended or worked at crowded places	21 (17.8)	12 (16.0)	
- Boxing stadium clusters	18 (15.3)	26 (34.7)	
- Healthcare facility	0	1 (1.3)	
- Unknown	4 (3.8)	4 (6.3)	
Smoking (n=157), n (%)			1.000
- Ever	17 (18.7)	12 (18.2)	
Alcohol use (n=164), n (%)			0.310
- Yes	33 (35.5)	19 (26.8)	
Coexisting conditions, n (%)			
- Any	13 (11.0)	35 (46.7)	<0.001
- Diabetes	4 (3.4)	12 (16.0)	0.003
- Hypertension	7 (5.9)	24 (32.0)	<0.001
- Dyslipidemia	3 (2.5)	7 (9.3)	0.050
- Allergy	1 (0.8)	1 (1.3)	1.000
- Chronic pulmonary diseases	1 (0.8)	2 (2.7)	0.561
- Chronic heart diseases	0	2 (2.7)	0.150
- Chronic liver diseases	1 (0.8)	4 (5.3)	0.076
- HIV infection	1 (0.8)	1 (1.3)	1.000
Angiotensin-converting enzyme inhibitors use, n (%)	3 (2.5)	3 (4.0)	0.679
Angiotensin-receptor blockers use, n (%)	3 (2.5)	8 (10.7)	0.025
Presenting symptoms, n (%)			

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/) .

- Fever	60 (50.8)	61 (81.3)	<0.001
- Dry cough	50 (42.4)	45 (60.0)	0.019
- Productive cough	22 (18.6)	19 (25.3)	0.283
- Shortness of breath	6 (6.8)	17 (22.7)	0.002
- Sore throat	42 (35.6)	12 (16.0)	0.003
- Rhinorrhea	41 (34.7)	14 (18.7)	0.022
- Fatigue	15 (12.7)	15 (20.0)	0.221
- Myalgia/body aches	32 (27.1)	37 (49.3)	0.002
- Headache	18 (15.3)	5 (6.7)	0.276
- Diarrhea	9 (7.6)	6 (8.0)	1.000
- Poor appetite	1 (0.8)	3 (4.0)	0.301
- Nausea or vomiting	1 (0.8)	4 (5.3)	0.076
- Reduced sense of taste	3 (2.5)	5 (6.7)	0.265
- Reduced sense of smell	7 (5.9)	4 (5.3)	1.000
- No symptoms	13 (11.0)	0	0.002
Body temperature at presentation, mean (\pm SD), °C	37.0 (0.6)	37.6 (1.0)	<0.001
Respiratory rate at presentation, median (IQR), breaths/min	18 (18-20)	20 (18-20)	0.001
Oxygen saturation at presentation, median (IQR), %	99 (98-100)	98 (97-99)	<0.001
Initial laboratory findings			
White blood cell count, median (IQR), $\times 10^9$ /L	5.9 (4.8-7.3)	5.8 (4.3-6.9)	0.298
Absolute neutrophil count, median (IQR), $\times 10^9$ /L	3.5 (2.7-4.8)	3.5 (2.6-5.2)	0.580
Absolute lymphocyte count, median (IQR), $\times 10^9$ /L	1.8 (1.3-2.2)	1.3 (0.9-1.7)	<0.001
Absolute monocyte count, median (IQR), $\times 10^9$ /L	0.4 (0.3-0.5)	0.3 (0.2-0.5)	0.413
Hemoglobin, median (IQR), g/dL	13.3 (12.6-14.0)	14.0 (12.5-15.0)	0.061
Platelet count, median (IQR), $\times 10^9$ /L	240 (194-247)	194 (157-226)	<0.001
Sodium level, median (IQR), mEq/L	140 (139-141)	138 (136-140)	0.004
Potassium level, median (IQR), mEq/L	4.0 (3.8-4.2)	3.8 (3.5-4.1)	0.005
Chlorine level, median (IQR), mEq/L	102 (101-104)	100 (97-103)	0.005
Bicarbonate level, median (IQR), mEq/L	24 (23-25)	24 (23-25)	0.435
Creatinine, median (IQR), mg/dL	0.7 (0.8-0.9)	0.9 (0.7-1.1)	<0.001
Aspartate aminotransferase, median (IQR), U/L	21 (18-25)	31 (23-43)	<0.001
Alanine aminotransferase, median (IQR), U/L	19 (13-25)	26 (19-42)	0.001
Outcomes			
Fever during hospitalization, n (%)	29 (24.6)	66 (88.0)	<0.001
Highest temperature during hospitalization, mean (\pm SD),	37.9 (0.5)	38.8 (0.8)	<0.001

°C			
Days from admission to defervescence, median (IQR),	3.0 (1.0-5.5)	6.0 (4.0-10.0)	<0.001
ICU admission n, (%)	0	32 (42.7)	<0.001
Days of hospitalization, median (IQR)	10.0 (6.8-16.0)	14.0 (10-23.0)	<0.001
Days of viral RNA shedding after onset of symptom, median (IQR)	14.0 (10-24.0)	18.0 (13.0-24.0)	0.023
Final clinical outcomes			0.002
Recovered, n (%)	118 (100)	71 (94.7)	
Deceased, n (%)	0	4 (5.3)	

289 Abbreviations: BMI, body mass index; HIV, human immunodeficiency virus

290 As summarized in Table 4, age (OR 2.55 per 10-year increase from 30 years old; 95%
 291 CI, 1.67-3.90; p<0.001), obesity (OR 8.74; 95% CI, 2.06-37.18; p=0.003), and body
 292 temperature at presentation (OR 4.59 per 1 °C increase from 37.2 °C; 95% CI, 2.30-9.17;
 293 p<0.001) were significantly associated with COVID-19 pneumonia.

294 **Table 4.** Logistic regression analysis of factors associated with COVID-19 pneumonia

	Crude OR (95%CI)	p-value	Adjusted (95%CI)	p-value
Gender				
Female	1			
Male	2.85 (1.52-5.32)	0.001	2.28 (0.79-6.56)	0.128
Age, for every 10-year increase from 30 years old	2.24 (1.73-2.90)	<0.001	2.55 (1.67-3.90)	<0.001
Body mass index (BMI)	1.20 (1.11-1.30)	<0.001		
- BMI < 30 kg/m ²	1			
- BMI ≥ 30 kg/m ² (obesity)	5.55 (2.05-15.06)	0.001	8.74 (2.06-37.18)	0.003
Nationality				
- Non-Thai	1			
- Thai	1.26 (0.11-14.16)	0.825		
Type of infection				
- Imported case	1			
- Local transmission case	0.94 (0.46-1.92)	0.868		
Transmission link				
- Contact with a confirm case	1			
- Travel history within 14 days before onset of	2.13 (0.91-4.95)	0.081		

symptom				
- Attended or worked at crowded places	1.82 (0.74-4.50)	0.194		
- Boxing stadium clusters	4.60 (2.02-10.48)	<0.001	1.02 (0.31-3.34)	0.968
- Unknown	3.19 (0.72-14.22)	0.129		
Smoking (vs never)	0.98 (0.43-2.19)	0.937		
Current alcohol use (vs no use)	0.66 (0.34-1.31)	0.235		
Coexisting conditions				
- Diabetes	5.43 (1.48-17.54)	0.005	1.12 (0.22-5.88)	0.890
- Hypertension	7.46 (3.02-18.44)	<0.001	1.08 (0.24-4.94)	0.925
- Dyslipidemia	3.95 (0.98-15.77)	0.052		
- Allergy	1.58 (0.10-25.67)	0.741		
- Chronic pulmonary diseases	3.21 (0.29-35.98)	0.345		
- Chronic liver diseases	6.60 (0.72-60.15)	0.095		
- HIV infection	1.58 (0.10-25.66)	0.747		
Angiotensin-converting enzyme inhibitors use	1.60 (0.31-8.13)	0.573		
Angiotensin-receptor blockers use*	4.58 (1.17-17.85)	0.028		
Body temperature at presentation, per 1°C increase from 37.2 °C	3.55 (2.23-5.64)	<0.001	4.59 (2.30-9.17)	<0.001
White blood cell count, x10 ⁹ /L	0.93 (0.79-1.08)	0.311		
Absolute neutrophil count, x10 ⁹ /L	1.06 (0.90-1.25)	0.512		
Absolute lymphocyte count, x10 ⁹ /L	0.28 (0.16-0.48)	<0.001		
- Absolute lymphocyte < 1,500 per mm ³	3.69 (2.00-6.82)	<0.001	1.73 (0.65-4.62)	0.276
Absolute monocyte count, x10 ⁹ /L	0.47 (0.09-2.48)	0.376		
Hemoglobin level, g/dL	1.19 (0.99-1.44)	0.07		
Platelet count, x10 ⁹ /L	0.99 (0.98-0.99)	<0.001		
- Platelet count < 150 per mm ³	9.84 (2.11-45.86)	0.004	4.03 (0.53-30.83)	0.169

295 * Angiotensin-receptor blockers use significantly correlated with hypertension (r=0.56, p<0.001)

296 Discussion

297 We describe the clinical spectrum and outcomes of 193 COVID-19 patients admitted at a
 298 national infectious institute in Thailand. More than half of the patients had a mild disease
 299 severity and the recovery rate of our cohort was 97.9% with a case fatality rate of 2.1%—
 300 only four deaths were observed in six critical patients. The overall incidence of pneumonia
 301 was 38.9%, of which 57.3% were not severe. Increasing age, obesity, and higher body

302 temperature were potential predictive factors for pneumonia in SARS-CoV-2 infected
303 patients.

304 Our cohort included laboratory-confirmed COVID-19 patients hospitalized regardless
305 of their disease severity. Findings from our study could be representative of the patients in the
306 full spectrum of the disease from the first presentation through to the final clinical outcomes.
307 A wide range of mortality of COVID-19 patients from 0 to 28% has been reported in
308 previous studies [3-5, 8, 9, 11, 12, 24], which may have resulted from selection bias of either
309 mild disease status or severe disease status along with a short observation period.

310 In the present study, approximately 40% of patients with SARS-CoV2 infection
311 developed pneumonia. This was much lower than incidence of pneumonia from SARS-CoV-
312 1 (78-90%) [25, 26]. We also found bilateral pneumonia was more prevalent than unilateral
313 pneumonia, which was different from Severe Acute Respiratory Syndrome (SARS) [27].
314 Older age is widely recognized to be associated with worse pneumonia [11, 28-30]. However,
315 obesity has been less explored so far. Obesity can impair immune responses to viral infection
316 [31, 32]. Kass, *et al.* found younger individuals with COVID-19 admitted to hospital were
317 more likely to be obese [33]. Chen, *et al.* reported those with obesity were more likely to
318 have severe condition [30]. We identified obesity was significantly associated with COVID-
319 19 pneumonia.

320 We found that fever was not a hallmark of COVID-19 but fever on admission was
321 significantly associated with pneumonia in the multivariate analysis. Although fever was the
322 most common presenting symptom, presenting fever on admission was less common in
323 patients with mild disease than those with moderate to severe disease. Among cases with
324 mild severity, only 29 (48.3%) of 60 cases who reported fever had a fever during
325 hospitalization. With a median duration from illness onset to the admission of five days, half

326 of the febrile patients with mild COVID-19 might have had a fever for less than five days.
327 Furthermore, we observed that patients with mild disease more frequently had sore throat and
328 rhinorrhea compared with those who were moderate to severe disease severities. These may
329 indicate that the virus is limited to the upper respiratory tract in patients with mild disease. Of
330 note, some patients with mild disease had advanced age and obesity.

331 Few studies have reported on the proportion of asymptomatic infection. Our study
332 revealed 13 patients who were asymptomatic at presentation, but three of them subsequently
333 developed symptoms and were recategorized as presymptomatic. Hence, the asymptomatic
334 infection was estimated to be 5% in our cohort, which differs from the previously published
335 reports in other settings (17.9-42.3%) [34, 35]. More information on the actual incidence of
336 asymptomatic infection among SARS-CoV-2 infected patients is needed. Interestingly, 30%
337 of asymptomatic cases in our cohort were more than 50 years of age. Determinants of disease
338 severity among the elderly required further investigation.

339 We did not intend to demonstrate the efficacy of a specific treatment on COVID-19.
340 Patients with mild to moderate disease received only supportive care and recovered. They
341 could be discharged, suggesting the self-limiting nature of the non-severe cases. While
342 published randomized trials on chloroquine, hydroxychloroquine, and lopinavir/ritonavir
343 have been unable to demonstrate treatment benefit [36-38], supportive care is crucial for
344 COVID-19 patients with the mild or moderate disease.

345 Understanding the full spectrum of COVID-19 is essential for estimating the
346 proportion of severe COVID-19 cases that require a large amount of healthcare resources.
347 Demand for hospital inpatient and ICU beds could be better predicted to mitigate the
348 overwhelming hospital burden after easing COVID-19 restriction. Although individuals

349 without risk factors who present with mild disease generally do not require hospitalization,
350 some of them might subsequently deteriorate.

351 This study has several limitations. First, the findings were based on a relatively small
352 sample size from a single center and may not be generalizable to other settings. However, the
353 proportion of patients in each category of the disease spectrum was comparable with those of
354 nationwide survey of China. This suggests that our sample may be representative of patients
355 with COVID-19 throughout the disease spectrum. Second, the study had risk of recall bias as
356 patients were asked to recall subjective events prior to admission. Third, not all blood
357 chemistry studies were performed in all patients and several non-routine tests (eg, serum
358 LDH, C-reactive protein, IL-6 level) were not investigated. Fourth, we used chest radiograph
359 as radiologic evidence of pneumonia. As chest radiograph is less sensitive than computed
360 tomography, the very mild pneumonia might have been missed. Likewise, arterial blood gas
361 was evaluated only in critical cases, so the incidence of ARDS may not have been correctly
362 estimated. Lastly, our institute has no testing facility for the viral load of SARS-CoV-2 so the
363 duration of viral RNA shedding may not represent the duration of viral viability.

364 In conclusion, the majority of patients with COVID-19 had mild illness. The
365 incidence of pneumonia of any severity was 39% (non-severe in 22%, severe in 14%, critical
366 in 3%). Most patients had a good final clinical outcomes. The case fatality rate in our cohort
367 was 2.1%. Increasing age, obesity, and higher temperature at presentation were potential
368 predictive factors of COVID-19 pneumonia.

369 **Acknowledgments**

370 The authors would like to thank Aroon Luaengniyomkul, Patama Suttha, Krittaecho
371 Siripassorn, Anuttra A Ratnarathon, and Suparat Khemnark for their invaluable support for

372 this study. We also greatly appreciate all the healthcare personnel at BIDI for their efforts in
373 providing the best care for our patients.

374 **Conflicts of interest**

375 None to declare

376 **Author Contributions**

377 **Conceptualization:** Wannarat A. Pongpirul, Surasak Wiboonchutikul

378 **Data Curation:** Wannarat A. Pongpirul, Surasak Wiboonchutikul, Lantharita Charoenpong,
379 Nayot Panitantum

380 **Formal analysis:** Wannarat A. Pongpirul, Surasak Wiboonchutikul

381 **Investigation:** Wannarat A. Pongpirul, Surasak Wiboonchutikul, Lantharita Charoenpong,
382 Nayot Panitantum

383 **Methodology:** Wannarat A. Pongpirul, Surasak Wiboonchutikul

384 **Project administration:** Apichart Vachiraphan

385 **Resources:** Wannarat A. Pongpirul, Surasak Wiboonchutikul, Lantharita Charoenpong,
386 Nayot Panitantum, Sumonmal Uttayamakul

387 **Supervision:** Weerawat Manosuthi, Wisit Prasithsirikul

388 **Validation:** Wannarat A. Pongpirul, Surasak Wiboonchutikul

389 **Visualization:** Wannarat A. Pongpirul, Surasak Wiboonchutikul

390 **Writing – original draft:** Wannarat A. Pongpirul, Surasak Wiboonchutikul, Lantharita
391 Charoenpong, Nayot Panitantum, Sumonmal Uttayamakul

392 **Writing – review & editing:** Krit Pongpirul, Weerawat Manosuthi, Wisit Prasithsirikul

393 **References**

- 394 1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from
395 Patients with Pneumonia in China, 2019. *N Engl J Med.* 2020;382(8):727-33.
- 396 2. World Health Organization. Novel Coronavirus – China. 2020 [cited 2020 May 30].
397 Available from: [https://www.who.int/csr/don/12-january-2020-novel-coronavirus-](https://www.who.int/csr/don/12-january-2020-novel-coronavirus-china/en/)
398 [china/en/](https://www.who.int/csr/don/12-january-2020-novel-coronavirus-china/en/)
- 399 3. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of
400 Coronavirus Disease 2019 in China. *N Engl J Med.* 2020;382(18):1708-20.
- 401 4. Tian S, Hu N, Lou J, Chen K, Kang X, Xiang Z, et al. Characteristics of COVID-19
402 infection in Beijing. *J Infect.* 2020;80(4):401-6.
- 403 5. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al.
404 Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients
405 Hospitalized With COVID-19 in the New York City Area. *JAMA.*
406 2020;323(20):2052-2059.
- 407 6. Wu J, Liu J, Zhao X, Liu C, Wang W, Wang D, et al. Clinical Characteristics of Imported
408 Cases of COVID-19 in Jiangsu Province: A Multicenter Descriptive Study. *Clin Infect*
409 *Dis.* 2020. Published online ahead of print, 2020 Feb 29
- 410 7. Hu L, Chen S, Fu Y, Gao Z, Long H, Wang JM, et al. Risk Factors Associated with
411 Clinical Outcomes in 323 COVID-19 Hospitalized Patients in Wuhan, China. *Clin Infect*
412 *Dis.* 2020. Published online ahead of print, 2020 May 3
- 413 8. Zhang J, Wang X, Jia X, Li J, Hu K, Chen G, et al. Risk factors for disease severity,
414 unimprovement, and mortality in COVID-19 patients in Wuhan, China. *Clin Microbiol*
415 *Infect.* 2020 Jun;26(6):767-72.

- 416 9. Wang X, Fang J, Zhu Y, Chen L, Ding F, Zhou R, et al. Clinical characteristics of non-
417 critically ill patients with novel coronavirus infection (COVID-19) in a Fangcang
418 Hospital. *Clin Microbiol Infect*. 2020. 2020;S1198-743X(20)30177-4.
- 419 10. Chen J, Qi T, Liu L, Ling Y, Qian Z, Li T, et al. Clinical progression of patients with
420 COVID-19 in Shanghai, China. *J Infect*. 2020;80(5):e1-e6.
- 421 11. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for
422 mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort
423 study. *Lancet*. 2020;395(10229):1054-62.
- 424 12. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138
425 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan,
426 China. *JAMA*. 2020. 2020;323(11):1061-1069.
- 427 13. World Health Organization. Clinical management of severe acute respiratory infection
428 (SARI) when COVID-19 disease is suspected: interim guidance, 13 March 2020. 2020
429 [cited 2020 April 23]. Available from: <https://apps.who.int/iris/handle/10665/331446>.
- 430 14. Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7).
431 *Chin Med J (Engl)*. 2020;133(9):1087-95.
- 432 15. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus
433 Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases
434 From the Chinese Center for Disease Control and Prevention. *JAMA*. 2020.
435 2020;10.1001/jama.2020.2648.
- 436 16. Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, et al. Experimental Treatment with
437 Favipiravir for COVID-19: An Open-Label Control Study. *Engineering (Beijing)*. 2020.
438 published online ahead of print, 2020 Mar 18.

- 439 17. World Health Organization. WHO Timeline - COVID-19. 2020 [cited 2020 May 30].
440 Available from: [https://www.who.int/news-room/detail/27-04-2020-who-timeline---](https://www.who.int/news-room/detail/27-04-2020-who-timeline---covid-19)
441 [covid-19](https://www.who.int/news-room/detail/27-04-2020-who-timeline---covid-19)
- 442 18. World Health Organization. COVID-19 - WHO Thailand Situation Reports. 2020 [cited
443 2020 May 30]. Available from: [https://www.who.int/thailand/emergencies/novel-](https://www.who.int/thailand/emergencies/novel-coronavirus-2019/situation-reports)
444 [coronavirus-2019/situation-reports](https://www.who.int/thailand/emergencies/novel-coronavirus-2019/situation-reports)
- 445 19. ARDS Definition Task Force, Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND,
446 Caldwell E, et al. Acute respiratory distress syndrome: the Berlin Definition. JAMA.
447 2012;307(23):2526-33.
- 448 20. Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin
449 Pract. 2012;120(4):c179-84.
- 450 21. World Health Organization. Obesity and overweight. [cited 2020 August 28]. Available
451 from <https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight>.
- 452 22. World Health Organization. Report of the WHO-China Joint Mission on Coronavirus
453 Disease 2019 (COVID-19). 2020 [cited 2020 April 23]. Available from:
454 [https://www.who.int/publications-detail/report-of-the-who-china-joint-mission-on-](https://www.who.int/publications-detail/report-of-the-who-china-joint-mission-on-coronavirus-disease-2019-(covid-19))
455 [coronavirus-disease-2019-\(covid-19\)](https://www.who.int/publications-detail/report-of-the-who-china-joint-mission-on-coronavirus-disease-2019-(covid-19))
- 456 23. Pongpirul WA, Mott JA, Woodring JV, Uyeki TM, MacArthur JR, Vachiraphan A, et al.
457 Clinical Characteristics of Patients Hospitalized with Coronavirus Disease, Thailand.
458 Emerg Infect Dis. 2020;26(7):10.3201/eid2607.200598.
- 459 24. Feng Y, Ling Y, Bai T, Xie Y, Huang J, Li J, et al. COVID-19 with Different Severities:
460 A Multicenter Study of Clinical Features. Am J Respir Crit Care Med.
461 2020;201(11):1380-8.
- 462 25. Lee N, Hui D, Wu A, Chan P, Cameron P, Joynt GM, et al. A major outbreak of severe
463 acute respiratory syndrome in Hong Kong. N Engl J Med. 2003;348(20):1986-94.

- 464 26. Booth CM, Matukas LM, Tomlinson GA, Rachlis AR, Rose DB, Dwosh HA, et al.
465 Clinical features and short-term outcomes of 144 patients with SARS in the greater
466 Toronto area. *JAMA*. 2003;289(21):2801-9.
- 467 27. Wong KT, Antonio GE, Hui DS, Lee N, Yuen EH, Wu A, et al. Severe acute respiratory
468 syndrome: radiographic appearances and pattern of progression in 138 patients.
469 *Radiology*. 2003;228(2):401-6.
- 470 28. Du RH, Liang LR, Yang CQ, Wang W, Cao TZ, Li M, et al. Predictors of mortality for
471 patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study.
472 *Eur Respir J*. 2020;55(5):2000524
- 473 29. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk Factors Associated With Acute
474 Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019
475 Pneumonia in Wuhan, China. *JAMA Intern Med*. 2020;e200994.
- 476 30. Chen Q, Zheng Z, Zhang C, Zhang X, Wu H, Wang J, et al. Clinical characteristics of 145
477 patients with corona virus disease 2019 (COVID-19) in Taizhou, Zhejiang, China.
478 *Infection*. 2020;1-9.
- 479 31. Honce R, Schultz-Cherry S. Impact of Obesity on Influenza A Virus Pathogenesis,
480 Immune Response, and Evolution. *Front Immunol*. 2019;10:1071.
- 481 32. Quante M, Dietrich A, ElKhal A, Tullius SG. Obesity-related immune responses and their
482 impact on surgical outcomes. *Int J Obes (Lond)*. 2015;39(6):877-83.
- 483 33. Kass DA, Duggal P, Cingolani O. Obesity could shift severe COVID-19 disease to
484 younger ages. *Lancet*. 2020;395(10236):1544-5.
- 485 34. Yang R, Gui X, Xiong Y. Comparison of Clinical Characteristics of Patients with
486 Asymptomatic vs Symptomatic Coronavirus Disease 2019 in Wuhan, China. *JAMA Netw*
487 *Open*. 2020;3(5):e2010182.

- 488 35. Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asymptomatic
489 proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond
490 Princess cruise ship, Yokohama, Japan, 2020. *Euro Surveill.* 2020;25(10):2000180.
- 491 36. Borba MGS, Val FFA, Sampaio VS, Alexandre MAA, Melo GC, Brito M, et al. Effect of
492 High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients
493 Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
494 Infection: A Randomized Clinical Trial. *JAMA Netw Open.* 2020;3(4):e208857.
- 495 37. Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W, et al. Hydroxychloroquine in patients
496 with mainly mild to moderate coronavirus disease 2019: open label, randomised
497 controlled trial. *BMJ.* 2020;369:m1849.
- 498 38. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A Trial of Lopinavir-Ritonavir in
499 Adults Hospitalized with Severe Covid-19. *N Engl J Med.* 2020;382(19):1787-99.

500